Biolegend, 141704, FITC anti-mouse CD206 (MMR) Antibody, 200μg

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.
200μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant mouse CD206 (MMR)
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality testedFC - Verified
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)
Application Notes: Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.
Application References(PubMed link indicates BioLegend citation): Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed Yang X, et al. 2015. PNAS. 112:2900. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed Liang S, et al. 2019. Mol Med Rep. 19:3707. PubMed Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed An S, et al. 2022. Int J Mol Sci. 23:. PubMed Chen H, et al. 2023. Nat Commun. 14:941. PubMed Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed Wang C, et al. 2023. Int J Oral Sci. 15:19. PubMed Yang Y, et al. 2023. Diagnostics (Basel). 13:. PubMed Yashchenko A, et al. 2023. Front Immunol. 14:1082078. PubMed Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed Yang Q, et al. 2022. Br J Pharmacol. 179:1661. PubMed Liang X, et al. 2022. Cancer Commun (Lond). 42:205. PubMed Luo XB, et al. 2022. Ann N Y Acad Sci. 1514:116. PubMed Pannunzio B, et al. 2022. Cells. 11: . PubMed Ding L, et al. 2023. Immunology. 168:49. PubMed Napier TS, et al. 2023. Biomedicines. 11: . PubMed Han J, et al. 2023. Front Microbiol. 13:1067725. PubMed Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed Kraynak CA, et al. 2022. Int J Pharm. 618:121634. PubMed Keane T, et al. 2012. Biomaterials. 33:1771. PubMed Miao L, et al. 2020. Theranostics. 0.7625. PubMed Meng W, et al. 2021. JCI Insight. 6:. PubMed Choi B, et al. 2017. Eur J Pharmacol. 10.1016/j.ejphar.2017.07.022. PubMed Song C, et al. 2019. Nat Commun. 10:3745. PubMed Kesavan R, et al. 2021. Int J Mol Sci. 22:. PubMed Zakeri A, et al. 2021. J Extracell Vesicles. 10:e12131. PubMed Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed Lee S, et al. 2015. PLoS One. 10: 0132329. PubMed Hindi S, et al. 2012. Mol Cell Biol. 32:4833. PubMed Wu R, et al. 2019. J Cell Mol Med. 24:1684. PubMed Li C, et al. 2022. Theranostics. 12:4581. PubMed Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed Zhang W, et al. 2021. Front Immunol. 12:688294. PubMed Wada I, et al. 2021. Invest Ophthalmol Vis Sci. 62:17. PubMed Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed Uroda T, et al. 2020. Nat Protoc. 15:2107. PubMed Li H, et al. 2019. J Immunol Res. 2018:4807145. PubMed Li K, et al. 2022. J Immunother Cancer. 10:. PubMed Yang Y, et al. 2022. Regen Biomater. 9:rbac023. PubMed Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed Shin JE, et al. 2021. Heliyon. 7:e08433. PubMed Nguyen TKT, et al. 2020. Am J Pathol. 286:190. PubMed Yin S, et al. 2016. Nat Commun. 7: 11311. PubMed Yin T, et al. 2016. Sci Rep. 18:19534. PubMed Linde N, et al. 2018. Nat Commun. 9:21. PubMed Amo-Aparicio J, et al. 2021. Theranostics. 11:9805. PubMed Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed Guo L, et al. 2021. Front Immunol. 12:785457. PubMed Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed Lu CS, et al. 2020. J Hematol Oncol. 0.584722222. PubMed Li N, et al. 2021. eLife. 10:00. PubMed Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed Zhang F, et al. 2017. Mol Immunol. 10.1016/j.molimm.2017.06.019. PubMed Shi R, et al. 2022. Theranostics. 12:875. PubMed Lee SS, et al. 2022. Commun Biol. 5:654. PubMed Sun L, et al. 2015. J Immunol. 194:4891. PubMed Kida Y, et al. 2013. J Am Soc Nephrol. 24:559. PubMed Wang W, et al. 2018. Oncogenesis. 7:97. PubMed Xie Z, et al. 2018. J Am Heart Assoc. 7:e007442. PubMed Lin S, et al. 2022. Nat Commun. 13:3301. PubMed Ishii H, et al. 2012. Cell Death Dis. 9;3:e363. PubMed Wang T, et al. 2018. Front Physiol. 9:209. PubMed Tomay F, et al. 2019. J Transl Med. 17:237. PubMed Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed Yang Y, et al. 2020. Cancer Biol Ther. 522:21. PubMed Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed Genoula M, et al. 2018. Front Immunol. 9:459. PubMed Zimmerman KA, et al. 2019. J Am Soc Nephrol. 30:1841. PubMed Zhou T, et al. 2022. Sci Adv. 8:eabj9617. PubMed Guan X, et al. 2022. Nat Commun. 13:2834. PubMed Shibata T, et al. 2020. J Clin Invest. 130:3021. PubMed Li Y, et al. 2015. Sci Rep. 5: 18648. PubMed Ano Y, et al. 2019. Nutrients. 1.959027778. PubMed Miki Y, et al. 2022. JCI Insight. 7:. PubMed Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed Liu Y, et al. 2015. BioMed Res Int. 2015 563425. PubMed Shen L, et al. 2016. Sci Rep. 6:30347. PubMed Cuccarese M, et al. 2017. Nat Commun. 8:14293. PubMed Yuan Y, et al. 2020. Front Physiol. 0.967361111. PubMed Laban H, et al. 2018. J Cell Biol. 217:1503. PubMed Makino A, et al. 2021. iScience. 24:103201. PubMed Wang S, et al. 2022. J Inflamm Res. 14:7107. PubMed Kaji T, et al. 2012. J Exp Med. 80:3642. PubMed Grayczyk JP et al. 2017. Cell host & microbe. 22(5):678-687 . PubMed Wang X, et al. 2021. Cell. 184:5357. PubMed de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed Wang S, et al. 2020. J Cell Mol Med. 24:722. PubMed Yoshida H, et al. 2019. Cell. 176:897. PubMed Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed Zhang A, et al. 2021. Theranostics. 11:3839. PubMed Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed Chen Y, et al. 2021. Cancer Cell. 39(4):548-565.e6. PubMed Xue YL, et al. 2020. J Cell Mol Med. 24:12341. PubMed Zhang J, et al. 2014. J Immunol. 193:5149. PubMed Fransén Pettersson N, et al. 2018. PLoS One. 13:e0203228. PubMed Hartwig T et al. 2017. Molecular cell. 65(4):730-742 . PubMed Gu L, et al. 2017. FASEB J. 31:3072. PubMed Perrotta C, et al. 2018. Front Immunol. 9:1186. PubMed McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed Medina-Buelvas DM, et al. 2021. Pathogens. 10:. PubMed Gao R, et al. 2021. J Clin Invest. 131:. PubMed Chen Z, et al. 2016. Innate Immunity. 22: 419 - 432. PubMed Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed Kim YD, et al. 2020. J Cancer. 11:4059. PubMed Kapralov AA, et al. 2020. Nat Chem Biol. 278:16. PubMed Li J, et al. 2021. eLife. 10:00. PubMed Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed Yao Y, et al. 2016. Mol Ther. 10.1038/mt.2016.36. PubMed Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed Xue Y, et al. 2020. Sci Rep. 10:22265. PubMed
RRID: AB_10900988 (BioLegend Cat. No. 141703) AB_10901166 (BioLegend Cat. No. 141704)
Structure: Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution: Macrophages, dendritic cells, Langerhans cells, liver endothelial cells
Function: Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor: Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type: Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area: Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family: CD Molecules
Antigen References: 1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501. 2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469. 3. Burgdorf S, et al. 2006. J. Immunol. 176:6770. 4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.
Gene ID: 17533
UniProt: View information about CD206 on UniProt.org
Clone: C068C2
Regulatory Status: RUO
Other Names: MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype: Rat IgG2a, κ
Q: Why is mouse CD206 stained intracellularly and not via surface staining?
A: Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.